

Effectiveness of two novel anionic and cationic platinum complexes in the treatment of osteosarcoma

著者	五十嵐 健太郎
著者別表示	Igarashi Kentaro
journal or publication title	博士論文本文Full
学位授与番号	13301甲第4275号
学位名	博士(医学)
学位授与年月日	2015-06-30
URL	http://hdl.handle.net/2297/45877



Effectiveness of Two Novel Anionic and Cationic Platinum Complexes in the Treatment of Osteosarcoma

Kentaro Igarashi¹, Norio Yamamoto¹, Katsuhiko Hayashi¹, Akihiko Takeuchi¹, Shinji Miwa¹, Akira Odani² and Hiroyuki Tsuchiya^{1,*}

¹Department of Orthopaedic Surgery; ²Division of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan

Abstract: *Aim:* This study aimed to characterize the cellular basis of the platinum cytotoxicity of two novel platinum complexes, 3Pt and 1Pt, in comparison with that of cisplatin. 3Pt comprises anionic phosphate moieties, while 1Pt comprises neutral aromatic ligands.

Methods: We compared the cytotoxic potency of 3Pt and 1Pt with that of cisplatin in osteosarcoma cell lines and an orthotopic mouse model.

Results: The cytotoxic potency of 3Pt was markedly higher than that of cisplatin in all cell lines. Both novel platinum complexes showed a complete lack of cross resistance in cisplatin-resistant cells. Caffeine enhanced the cytotoxic potency of these novel platinum complexes, as observed for cisplatin. Apoptosis after drug administration was observed by DNA ladder formation and an annexin V/PI assay. DNA double-strand breaks were confirmed by phosphorylation of histone H2AX. *In vivo*, the antitumor activity of 3Pt and 1Pt was superior and similar, respectively, to that of cisplatin. Both novel platinum complexes exerted strong antitumor effects on osteosarcoma *in vitro* and *in vivo*.

Conclusions: 3Pt may be an effective drug for the treatment of bone cancer because the PO₃ moiety has a high affinity to bone, as exhibited by bisphosphonates, and is expected to decrease the incidence of side effects at extraskelatal sites and overcome drug resistance. Cationic 1Pt may also be an effective antitumor drug because of its unique chemical structure and properties. Further investigations to detail the antitumor effects of these ionic Pt complexes on osteosarcoma are warranted.

Keywords: Antitumor, bone-targeting platinum, cisplatin resistance, DNA interaction, osteosarcoma, platinum complex, proteasome inhibitory platinum.



BACKGROUND

For nearly 30 years, cisplatin has been one of the most effective antitumor agents available for the treatment of solid human tumors, including osteosarcoma [1]. However, some tumors are intrinsically resistant to cisplatin, and the development of resistance presents a major clinical barrier to effective treatment [2]. The efficacy of cisplatin is also limited by side effects such as dose-dependent renal toxicity and hematotoxicity.

Osteosarcoma is a common malignant primary bone tumor that develops in patients aged 10–25 years, and its prognosis has improved significantly with advances in chemotherapy and local surgical control [3]. Since 1989, our research group has published reports on caffeine-potentiated chemotherapy. Caffeine, a trimethyl-substituted xanthine, enhances the damage to cellular DNA and may inhibit the post-replication repair of sublethally damaged DNA [4]. Although the 5-year survival rate for nonmetastatic osteosarcoma in our department has improved to 90% with caffeine-potentiated chemotherapy [5–7], the prognoses of recurrent and metastatic osteosarcoma remain poor, with a long-term survival rate of >20% [8–11].

Recently, we designed several platinum-based chemotherapy agents using new concepts [12]. Ionic platinum complexes were prepared to increase solubility and avoid platinum nephrotoxicity. Bisphosphonates, metabolically stable pyrophosphate analogs, are known for their bone-targeting properties and are used as therapeutic agents for bone diseases such as osteoporosis and bone

metastasis [13, 14]. Bisphosphonates have a strong affinity for calcium and show strong inhibition to osteoclastic resorption [15]. Therefore, we incorporated bisphosphonates into a platinum complex to target bone tissue.

Another design was based on the structure of the cisplatin-DNA(-G-G)-HMG (high mobility group) protein adduct [16], where aromatic ring stacking played an important role in adduct formation. The formed adduct is a key to escape attack by the DNA repair enzyme complex. Among the new protein targets, the proteasome may be a major target of 1Pt because of its strong inhibitory capabilities [12]. The proteasome is involved in the regulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B) activity and drives several anti-apoptotic activities and oncogenic factor expression [17].

OBJECTIVES

In this study, we analyzed the antitumor effects of two novel platinum complexes, 3Pt and 1Pt (Fig. 1) [12], on osteosarcoma and compared their efficacy with that of cisplatin both *in vitro* and *in vivo*.

MATERIALS AND METHODS

Ethics Statement

The animal study was conducted in accordance with the Guidelines on the Care and Use of Laboratory Animals issued by Kanazawa University. The protocol was approved by the ethical committee of Kanazawa University (permit number: AP-112171). All surgeries were performed under sodium pentobarbital anesthesia. All efforts were made to minimize animal suffering, to decrease the number of animals used, and to utilize possible alternatives to *in vivo* techniques.

*Address correspondence to this author at the Department of Orthopedic Surgery, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8641, Japan; Tel: +81-76-265-2374; Fax: +81-76-234-4261; E-mail: tsuchi@med.kanazawa-u.ac.jp




Fig. (1). Structures of the novel platinum compound 1Pt and 3Pt.

DRUGS

Both novel platinum drugs were synthesized by Professor Odani at the Division of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan.

1Pt ([Pt(5-methyl-1,10-phenanthroline)(N-(9-anthracenylmethyl)-trimethylenediamine(AtC3))] C12 Synthesis

For 1Pt synthesis, 0.42 g (1.3 mM) N-(9-anthracenylmethyl)-trimethylenediamine(AtC3)·2 HCl, 0.16 g (1.5 mM) Na₂CO₃ in 10 mL H₂O, and 5 mL EtOH were added to a suspension of Pt(5-methyl-1,10-phenanthroline(MP))Cl₂ (0.46 g, 1.0 mM) in 10 mL H₂O, and the mixture was stirred for approximately 3 hrs at 80 °C. The black mixture was filtered while still hot to remove undissolved materials. After cooling to room temperature, the filtrate was evaporated till it decreased to 1–2 mL and acetone was added to the residue. After standing the residue overnight in a refrigerator, a pale yellow precipitate was formed, which was collected on a filter and dried under a vacuum to maintain the structure of the metal complex, which yielded 0.49 g (62%).

Elemental analysis: C₃₁H₃₀N₄PtCl₂·5 H₂O·0.5 NaCl

Observed: C, 44.14%; H, 4.30%; N, 6.26%

Calculated: C, 43.64%; H, 4.81%; N, 6.57%

Structure confirmations: The structure of 1Pt was indicated in Fig. 1 by H-NMR of 1Pt(Pt-Mphen-AtC3 complex) showed 2 signals with same intensity, which indicated two geometric isomers in square planar complex (cis-trans isomers).

¹H-NMR (D₂O)

8.85 (d, 1H), 8.75 (d, 1H), 8.66 (m, 4H), 8.36 (d, 1H), 8.28 (d, 2H), 8.16 (d, 1H), 7.94 (m, 3H), 7.83 (t, 2H), 7.70 (m, 6H), 7.62 (s, 1H), 6.95 (m, 4H), 6.74 (m, 2H), 6.53 (m, 2H), 6.42 (m, 2H), 5.43 (d, 2H), 3.62 (m, 2H), 3.44 (m, 2H), 3.28 (m, 2H), 3.03 (m, 2H), 2.73 (s, 3H), 2.67 (s, 3H), 2.51 (m, 4H).

¹³C-NMR (D₂O)

19.96(1C), 27.05(1C), 45.62(1C), 53.19(1C), 55.93(1C),

124.86(1C), 125.51(1C), 126.57(2C), 127.80(3C), 131.07(3C), 132.12(3C),

138.07(1C), 140.12(1C), 142.20(1C), 144.69(1C), 145.56(1C), 146.49(1C), 147.12(2C), 147.91(1C), 148.23(1C), 149.13(1C), 149.62(1C), 164.99(1C)

3Pt ([Pt(Pt(1R,2R-diaminocyclohexane)(myo-inositol-1,2,3,4,5,6-hexakisphosphate))₂] Synthesis

For 3Pt synthesis, Ag(NO₃) (0.01 g, 0.07 mM) was dissolved in 1 mL H₂O and added to K₂PtCl₄ (0.01 g, 0.03 mM) in 2 mL H₂O, and the mixture was stirred overnight. Pt(Pt(1R,2R-diaminocyclohexane(dach)) (myo-inositol-1,2,3,4,5,6-hexakisphosphate (IP6))·10 Na·14 H₂O (0.10 g, 0.07 mM) in 1 mL H₂O was added to the solution and stirred for 2–3 days at 50 °C. After removal of AgCl by filtration, the filtrate was evaporated and MeOH was added to the residue. The off-white powder was collected and dried under a vacuum to maintain the structure of the metal complex, which yielded 0.06 g (50%).

Elemental analysis: C₁₆H₇₈N₄O₆₅P₆Tp₃Na₁₈ (Pt(Pt(dach)IP6)₂·18 Na·2 CH₃OH·15 H₂O)

Observed: C, 10.90%; H, 2.75%; N, 1.96%

Calculated: C, 11.30%; H, 3.17%; N, 1.83%

Structure confirmations: The structure of 3Pt was indicated in Fig. 1 by P-NMR which showed 6 signals with same intensity and the two P signals at 2 and 3 in IP6 were not shifted by pH change.

¹H-NMR (D₂O)

dach: 1.158(t,br,4H), 1.301(s,br, 4H), 1.578(s, br, 4H), 2.056(t, br, 4H), 2.406(m, br, 4H) ;

IP6: 3.78(m, 2H), 4.03(m, 6H), 4.38(m, 4H)

¹³C-NMR (D₂O):

dach: 26.78(4C), 34.63(4C), 65.77(4C),

IP6: 73.88(1C), 74.52(1C), 76.19(4C), 77.70(2C), 78.55(2C), 79.64(1C), 80.31(1C)

Cell Lines and Growth Conditions

The LM8, MG63, and 143B osteosarcoma cell lines were used for the experiments. The murine osteosarcoma cell line LM8 was provided by the RIKEN Tsukuba Institute BioResource Center (Ibaraki, Japan) through the National Bio-Resource Project of the Ministry of Education, Culture, Sports, Science, and Technology of Japan. All other cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA). The osteosarcoma sublines LM8cisR, 143BcisR, and MG63cisR were established by exposing the cisplatin-sensitive osteosarcoma cell lines to successive increments in cisplatin concentrations. Resistance was stable in the absence of the selecting agent for at least 3 months. Cells were maintained in the log phase by supplementation with fresh medium 2–3 times/week. All cells were grown in Roswell Park Memorial Institute 1640 medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin.

Growth Inhibition Assay

Cellular viability was assessed using the 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST-8) dye reduction assay. Briefly, cells were seeded in 96-well flat-bottomed microplates (100 µL/well) at 5×10^4 cells/mL, incubated for 24 hrs at 37 °C, and exposed to various concentrations of the test compounds for 72 hrs. For each concentration, at least eight wells were used. After incubation with the test compounds, 10 µL of WST-8 solution was added to each well. The microplates were further incubated for 3 hrs at 37°C, and absorption was measured using a microprocessor-controlled microplate reader (iMark™; Bio-Rad Laboratories, Hercules, CA, USA) at 450 nm. Half maximal inhibitory concentration (IC₅₀) values were derived from dose–response curves.

Apoptosis Assay

DNA fragmentation was analyzed by agarose gel electrophoresis. Osteosarcoma cells were exposed for 48 h to 12.5 µM of each test compound. DNA was extracted using the Apoptotic DNA ladder kit (catalog no.: 11 835 264; Roche Applied Science, Indianapolis, IN, USA) according to the manufacturer's instructions. The extracted DNA was electrophoresed on a 1.5% agarose gel containing 1 µg/mL of ethidium bromide at 100 V. The DNA fragments were visualized by exposing the gel to ultraviolet light and photographed.

Flow cytometric assessment of annexin V binding to apoptotic cells was determined by assessing phosphatidylserine exposure to annexin V-fluorescein isothiocyanate (FITC) binding using the Annexin V-FITC staining kit (catalog no.: IM3546; Beckman Coulter, Fullerton, CA, USA) according to the manufacturer's instructions. Cells (10^4) were analyzed in a flow cytometer (desk top cell sorter JSAN; Bay Bioscience Co., Ltd., Hyogo, Japan). Annexin V is used to identify cells in all stages of programmed cell death [18,19]. Propidium iodide (PI) exclusively stains cells with disrupted membranes and is used to identify late apoptotic and dead cells.

Gamma-H2AX (γ-H2AX) Immunofluorescence Staining

Cells were grown to 70% confluence in 4-well Lab-Tec Chamber Slides (Nunc, Naperville, IL, USA) and cultured for 24 hrs in the presence of 10 µM of each compound. At each time point, the cells were fixed. The slides were washed and incubated with mouse monoclonal antibodies to histone γ-H2AX (dilution, 1:300; Upstate Biotechnology, Lake Placid, NY, USA), followed by incubation with Alexa Fluor 488-labeled goat antibodies conjugated to mouse immunoglobulin G (dilution, 1:700; Molecular Probes, Eugene, OR, USA). The slides were mounted in fluorescence mounting medium (Dako Cytomation, Hamburg, Germany), and the fluorescent

signals were visualized using confocal laser scanning microscopy (BZ-9000; Keyence Corporation, Osaka, Japan). Three random fields, each containing at least 100 cells, were examined at 100× magnification. Nuclei containing ≥10 immunoreactive foci were counted as γ-H2AX-positive, and the percentage of positive cells was determined [20].

ORTHOTOPIC MOUSE MODEL

Animals

Female nude mice (BALB/c-nu/nu) aged 4–6 weeks were purchased from Sankyo Laboratory Inc. (Toyama, Japan) and housed in a barrier facility under high-efficiency particulate air filtration. The mice were bred under germ-free and specific pathogen-free conditions. The animal study was conducted in accordance with the Guidelines on the Care and Use of Laboratory Animals issued by Kanazawa University. The protocol was approved by the ethical committee of Kanazawa University (permit number: AP-112171). All surgeries were performed under sodium pentobarbital anesthesia. All efforts were made to minimize animal suffering, to reduce the number of animals used, and to utilize possible alternatives to *in vivo* techniques.

Intratibial 143B Transplantation

For intratibial transplantation, cells were suspended in 10 µL of PBS containing 5 µg of Matrigel™ Basement Membrane Matrix (Becton Dickinson, Bedford, MA, USA) to prevent the suspension from leaking out. A suspension of 2×10^5 143B cells was implanted. All mice were checked and weighed daily, and tumors were measured once weekly using digital calipers. Two weeks after transplantation, mice were treated intraperitoneally with cisplatin (20 µM/kg), 1Pt (20 µM/kg), 3Pt (15 µM/kg), or normal saline (n = 8 each). We administered the compounds 1 day per week. Treatments were repeated weekly for 3 weeks. Six weeks after transplantation, all mice were sacrificed.

Primary Tumor Growth

Tumor volumes were calculated using the following equation: volume = $4\pi (A/2)(B/2)(C/2)/3$, where A is the width (average distance in the medial–lateral plane), B is the length (average distance in the proximal–distal plane), and C is the width (average distance in the anterior–posterior plane).

Statistical Analysis

Data are presented as means ± standard deviation and were compared between groups using the unpaired Student's t-test. A P-value of <0.05 was considered statistically significant.

RESULTS

Cytotoxicity

The cytotoxic activity of cisplatin, 1Pt, and 3Pt was determined in the 143B, MG63, LM8, 143BcisR, MG63cisR, and LM8cisR osteosarcoma cell lines, which were incubated for 72 h with the platinum-based compounds. Cell survival was evaluated as described in the Materials and Methods section. Each compound significantly inhibited cisplatin-susceptible cell growth in a dose-dependent manner (Fig. 2). The IC₅₀ value of 3Pt was significantly lower than that of cisplatin, and the cytotoxic activity of each compound was potentiated by adding 1 mM caffeine (Table 1). Cisplatin resistance was approximately 2.85-fold, with IC₅₀ values of LM8 and LM8cisR cells. The resistance index (RI) was 2.85 for LM8cisR, 1.83 for 143BcisR, and 4.17 for MG63cisR (Fig. 3, Table 2). 3Pt potency was markedly higher than cisplatin potency in LM8, 143B, and MG63 cells, whereas 1Pt and 3Pt completely




Fig. (2). Growth inhibition assay of each platinum complex against LM8, MG63, and 143B cells Osteosarcoma cells were incubated with cisplatin, 1Pt, or 3Pt for 72 hrs and evaluated using the WST-8 assay.

Table 1. IC₅₀ value of cisplatin and 1Pt, 3Pt against LM8, MG63, and 143B cells with and without adding 1mM of caffeine.

	CDDP IC ₅₀ (μM)		1Pt IC ₅₀ (μM)		3Pt IC ₅₀ (μM)	
		+CAF 1mM		+CAF 1mM		+CAF 1mM
LM8	1.09±0.24	0.47±0.10**	3.38±0.49	1.46±0.29**	0.12±0.01	0.068±0.015**
MG63	1.85±0.48	1.02±0.09**	3.40±0.47	2.32±0.20**	0.72±0.15	0.48±0.07**
143B	2.19±0.15	1.24±0.10**	5.83±0.30	3.31±0.53*	0.62±0.07	0.48±0.08**

Osteosarcoma cells were incubated with either platinum complex with and without caffeine for 72 hrs and then assessed *via* the WST-8 assay.

Table 2. IC₅₀ value of cisplatin and 1Pt, 3Pt against LM8, MG63, 143B, LM8cisR, MG63cisR, 143BcisR cells.

Drug	LM8 IC ₅₀ (μM)	LM8-cisR IC ₅₀ (μM)	RI	MG63 IC ₅₀ (μM)	MG63-cisR IC ₅₀ (μM)	RI	143B IC ₅₀ (μM)	143B-cisR IC ₅₀ (μM)	RI
CDDP	1.20±0.06	3.41±0.10	2.85	1.09±0.06	4.53±0.21	4.17	1.00±0.03	1.83±0.10	1.83
1Pt	2.72±0.18	2.74±0.13	1.01	2.47±0.12	2.41±0.11	0.97	2.10±0.05	1.97±0.10	0.93
3Pt	0.050±0.006	0.049±0.004	0.98	0.173±0.014	0.178±0.021	1.03	0.091±0.007	0.078±0.007	0.85

RI(resistance index)=cisplatin-resistant/cisplatin-sensitive IC₅₀. Osteosarcoma cells were incubated with cisplatin, 1Pt, or 3Pt for 72 hrs and assessed by the WST-8 assay.




Fig. (3). A growth inhibition assay of each platinum complex against the MG63, MG63cisR cell lines. Osteosarcoma cells were incubated with cisplatin, 1Pt, or 3Pt for 72 hrs and assessed by the WST-8 assay.




Fig. (4). Agarose gel electrophoresis for analysis of DNA fragmentation induced by the platinum complexes. Osteosarcoma cells were exposed to 12.5 μM of each compound for 48 hrs. DNA was extracted and electrophoresed in an agarose gel. The DNA fragments were then visualized by exposing the gel to ultraviolet light.




Fig. (5). The annexin V-FITC/PI assay to assess apoptosis of 143B cells induced by the platinum complexes. 143B cells were exposed to each compound for 24 hrs, and flow cytometry assay was performed using an annexin V-FITC/PI assay kit.

lacked cross-resistance in LM8cisR, 143BcisR, and MG63cisR cells.

Apoptosis Induction

Treatment with each platinum complex for 48 hrs resulted in DNA ladder formation (Fig. 4). After the 24-hrs treatment, cisplatin and 1Pt demonstrated early apoptosis at a 10 μ M concentration,

whereas 3Pt showed early and late apoptosis at lower concentrations compared with cisplatin (Fig. 5).

γ -H2AX Immunofluorescence Staining

The effect of cisplatin is induced through DNA damage [21]. Because the chemical structures of 1Pt and 3Pt are quite different from those of cisplatin, we determined whether 1Pt and 3Pt induced




Fig. (6). A. Formation of gamma-H2AX foci induced by the platinum complexes in 143B cells. The cells were incubated with each platinum complex for 48 h, fixed, and subjected to immunofluorescence staining for γ -H2AX. B. Formation of gamma-H2AX foci induced by the platinum complexes in LM8, MG63 and 143B cells. They were then fixed and subjected to immunofluorescence staining for gamma-H2AX and the percentage of cells containing gamma-H2AX foci was determined. Data are means \pm s.e.




Fig. (7). *In vivo* antitumor effects of the platinum complexes. 143B cells were transplanted into the tibia of nude mice and allowed to form tumors, following which the mice were assigned to 1 of 4 treatment groups (control, cisplatin, 1Pt, or 3Pt) as described in Materials and Methods section. Tumor volume was measured at the indicated time points after the onset of treatment. All data are presented as mean±standard deviation for 8 mice/group.

H2AX phosphorylation to yield γ -H2AX, a marker of DNA double-strand breaks. 143B, MG63, and LM8 cell exposure to 1Pt or 3Pt resulted in gradual γ -H2AX foci accumulation, similar to the effects of cisplatin (Fig. 6A, B).

Orthotopic Mouse Model

143B cells were transplanted intratibially in nude mice. At 6 weeks, 143B tumor treatment with 3Pt resulted in the largest, most significant, and most effective decrease in tumor volume compared with no treatment. 1Pt demonstrated almost the same effects as those of cisplatin. There were no animal deaths in any group (Fig. 7).

DISCUSSION

Cisplatin received clinical approval in 1978 and remains as one of the most powerful drugs for the treatment of testicular and ovarian cancer since then. Widespread clinical cisplatin use for malignant tumors has prompted a search for new platinum agents. Currently, carboplatin and oxaliplatin are widely applied clinically, although their clinical use against osteosarcoma has been limited. Direct cisplatin analogs interact with DNA-processing proteins in a similar manner as the parent drug. Differences in antitumor activities and toxicities may be mediated by differences in pharmacokinetics or reactivity rather than increased DNA function inhibition. Platinum compounds that are structurally different from cisplatin may form different platinum-DNA adduct types; however, they exhibit a spectrum of clinical activity complementary to that of the parent drug, such as the two novel Pt drugs described here.

In this study, the antitumor effects of the two novel platinum complexes were evaluated against osteosarcoma cell lines and in an orthotopic mouse model. Each complex exhibited excellent organic and aqueous solution solubility.

The results of the present study showed that both complexes demonstrated strong antitumor activity. The cytotoxic potency of 3Pt was markedly higher than that of cisplatin. The detection of apoptosis by annexin V-FITC revealed that 3Pt inhibited 143B cell

proliferation by increasing the apoptotic and necrotic cell number and that the apoptotic effect of cisplatin was weak.

Some studies reported varied cytotoxicity levels depending on the Pt complex structure [22]. A recent review explained how small changes in molecular structure can cause profound differences in biological activity [23]. Traditionally, few platinum cation complexes possess antitumor effects. However, a recent study on charged trinuclear cation platinum BBR3464 revealed that charge incorporation into the linker backbone and hydrogen-bonding capacity increased DNA affinity [24]. These features contribute to different DNA binding, cellular uptake, and antitumor activities within the polynuclear platinum family. Since 3Pt is an unusual trinuclear anion complex, it is expected to involve specific drug–bone interactions.

Cisplatin adducts and analogs distort DNA conformation [25, 26], inhibit replication and transcription [27, 28], and induce apoptosis or necrosis [29]. In addition, cisplatin adducts are removed from DNA mainly by the nucleotide excision repair system [30]. Although changes in the association process with DNA may exist, 1Pt and 3Pt cause dose-dependent apoptosis, similar to cisplatin. H2AX phosphorylation after drug administration was also found to be time-dependent.

Cisplatin efficacy against malignant tumors is limited because of resistance, either intrinsic or acquired. The mechanism underlying cisplatin resistance appears to be multifactorial because cancer cells can develop cisplatin resistance through changes in drug transport, enhanced drug detoxification systems, and changes in DNA repair mechanisms, such as increased nucleotide excision repair, interstrand crosslink repair, and mismatch repair loss [31, 32]. Both novel platinum complexes showed efficacy against cisplatin-resistant cells. These antitumor activities against cisplatin-resistant cell lines suggested the ability to overcome the multiple mechanisms underlying cisplatin resistance. 3Pt was designed to target bone tissue and contains germinal bisphosphonate moieties for drug delivery, even if in low concentrations. Although antitumor activity at such low bisphosphonate concentrations may be nil, 3Pt is expected to be delivered to bone and bone-forming tumors more

effectively. Because 3Pt is also effective against many cancer cell lines, it may be effective against bone metastases.

Among the new protein targets, the proteasome may be a major target of 1Pt because of its strong inhibition [12].

1Pt showed strong antitumor activities by inducing DNA double-strand breaks, similar to cisplatin. However, 1Pt could not coordinate DNA because no ligand-exchange reaction was observed using H1-NMR on mixing 1Pt and guanosine 5'-phosphate (5'-GMP). Then, the DNA event may occur after 1Pt interacts noncovalently with DNA and protein, as estimated in structurally similar Pt compounds such as Pt(56-dimethylphenanthroline)(s-dach) [33-35]. Among the possible protein targets, such as kinase, telomerase, and proteasome, the proteasome may be a major target of 1Pt because Cu-phenanthroline (amino acid) exhibits a coordination structure similar to that of 1Pt and was reported to demonstrate proteasome inhibition [36]. The proteasome inhibitory activity has not received much attention because the proteasome inhibitor enhances the transport of the drug to the nuclei and is expected to act synergistically with the drug [37]. Proteasome inhibition by covalent bonding to the boronic acid moiety of the clinical drug bortezomib is well known; however, the problem of drug resistance led to the development of a noncovalent-type inhibitor [38].

Bortezomib, a boronic acid dipeptide, was the first proteasome inhibitor approved by the U.S. Food and Drug Administration for myeloma treatment [39]. The proteasome is the primary component of the protein degradation pathway. Through the degradation of regulatory proteins, the proteasome serves as a central conduit for many cellular regulatory signals; therefore, it is an attractive therapeutic drug target. The NF-kappa B signaling pathway may be a critical target for proteasome inhibitors. This repression is released in response to cellular stresses that cause targeted proteasome-induced I-kappa B degradation to release NF-kappa B [40-44], which is rapidly translocated to the nucleus where it increases production of cytokines, including vascular endothelial growth factor, tumor necrosis factor, interleukin-1, interleukin-6, and cell adhesion molecules. NF-kappa B can also increase anti-apoptotic expression of Bcl-2 protein family members [45-48]. Dysregulation of NF-kappa B signaling is an important feature of malignancy [49, 50], and proteasome inhibitors produce antitumor effects by causing direct tumor cell apoptosis and exerting effects on the tumor microenvironment, such as anti-angiogenesis. Furthermore, bortezomib suppresses growth and induces apoptosis in osteosarcoma both *in vitro* and *in vivo* [51]. Therefore, proteasome inhibitors are interesting drug candidates for the treatment of osteosarcoma, considering that 1Pt showed strong antitumor activity in the orthotopic mouse model through probable proteasome inhibition.

CONCLUSIONS

We developed two novel platinum complexes that exhibited powerful antitumor effects against osteosarcoma cell lines and in an orthotopic mouse model. Therefore, these novel Pt complexes may represent a new class of potent antisarcoma agents. In addition enhanced chemotherapy by caffeine addition was possible. However, further *in vitro* studies are required to unravel the putative mechanisms underlying their actions, including DNA interactions.

CONFLICT OF INTEREST

The author(s) confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

This research was supported by The Mitani Foundation for Research and Development, and Basic Science Research Program through the National Research Foundation of Japan funded by the

Ministry of Education, Culture, Sports, Science, and Technology of Japan.

REFERENCES

- [1] Yamamoto, N.; Tsuchiya, H. Chemotherapy for osteosarcoma - where does it come from? What is it? Where is it going? *Exp. Opin. Pharmacother.*, **2013**, *14*(16), 2183-2193.
- [2] Shen, D.W.; Pouliot, L.M.; Hall, M.D.; Gottesman, M.M. Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. *Pharmacol. Rev.*, **2012**, *64*(3), 706-721.
- [3] Jaffe, N. Osteosarcoma: Review of the past, impact on the future. The American experience. *Cancer Treat. Res.*, **2009**, *152*, 239-262.
- [4] Bode, A.M.; Dong, Z. The enigmatic effects of caffeine in cell cycle and cancer. *Cancer Lett.*, **2007**, *247*, 26-39.
- [5] Tsuchiya, H.; Tomita, K.; Mori, Y.; Asada, N.; Yamamoto, N. Marginal excision for osteosarcoma with caffeine assisted chemotherapy. *Clin. Orthop.*, **1999**, *358*, 27-35.
- [6] Hayashi, K.; Tsuchiya, H.; Yamamoto, N.; Shirai, T.; Yamauchi, K.; Takeuchi, A.; Kawahara, M.; Miyamoto, K.; Tomita, K. Impact of serum caffeine monitoring on adverse effects and chemotherapeutic responses to caffeine-potentiated chemotherapy for osteosarcoma. *J. Orthop. Sci.*, **2009**, *14*, 253-258.
- [7] Kimura, H.; Tsuchiya, H.; Shirai, T.; Nishida, H.; Hayashi, K.; Takeuchi, A.; Ohnari, I.; Tomita, K. Caffeine-potentiated chemotherapy for metastatic osteosarcoma. *J. Orthop. Sci.*, **2009**, *14*, 556-565.
- [8] Bacci, G.; Briccoli, A.; Ferrari, S.; Longhi, A.; Mercuri, M.; Capanna, R.; Donati, D.; Lari, S.; Forni, C.; DePaolis, M. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. *Eur. J. Cancer.*, **2001**, *37*(16), 2030-2039.
- [9] Iwamoto, Y.; Tanaka, K.; Iku, K.; Kawai, A.; Tatezaki, S.; Ishii, T.; Kushida, K.; Beppu, Y.; Usui, M.; Tateishi, A.; Furuse, K.; Minamizaki, T.; Kawaguchi, N.; Yamawaki, S. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. *J. Orthop. Sci.*, **2009**, *14*(4), 397-404.
- [10] Ferrari, S.; Ruggieri, P.; Cefalo, G.; Tamburini, A.; Capanna, R.; Fagioli, F.; Comandone, A.; Bertulli, R.; Bisogno, G.; Palmerini, E.; Alberghini, M.; Parafioriti, A.; Linari, A.; Picci, P.; Bacci, G. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. *J. Clin. Oncol.*, **2012**, *30*, 2112-2118.
- [11] Durnali, A.; Alkis, N.; Cangur, S.; Yukruk, F.A.; Inal, A.; Tokluoglu, S.; Seker, M.M.; Bal, O.; Akman, T.; Inanc, M.; Isikdogan, A.; Demirci, A.; Helvacı, K.; Oksuzoglu, B. Prognostic factors for teenage and adult patients with high-grade osteosarcoma: An analysis of 240 patients. *Med. Oncol.*, **2013**, 624.
- [12] A, Odani. Metal complexes and anticancer agents comprising same as active ingredient, Patent WO 2011125911 A1. 2011-10-13
- [13] McClung, M.; Harris, ST.; Miller, P.D.; Bauer, D.C.; Davison, K.S.; Dian, L.; Hanley, D.A.; Kendler, D.L.; Yuen, C.K. Lewiecki EM. Bisphosphonate therapy for osteoporosis: Benefits, risks, and drug holiday. *Am. J. Med.*, **2013**, *126*(1), 13-20.
- [14] Holen, I.; Coleman, R.E. Bisphosphonates as treatment of bone metastases. *Curr. Pharm. Des.*, **2010**, *16*(11), 1262-1271.
- [15] Jobke, B.; Milovanovic, P.; Amling, M.; Busse, B. Bisphosphonate-osteoclasts: Changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients. *Bone*, **2014**, *59*, 37-43.
- [16] Park, S.; Lippard, S.J. Binding Interaction of HMGB4 with Cisplatin-Modified DNA. *Biochemistry*, **2012**, *51*(34), 6728-6737.
- [17] Sunwoo, J.B.; Chen, Z.; Dong, G.; Yeh, N.; Crowl Bancroft, C.; Sausville, E.; Adams, J.; Elliott, P.; Van Waes, C. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor- κ B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. *Clin. Cancer Res.*, **2001**, *7*(5), 1419-1428.
- [18] Westermann, B. Molecular machinery of mitochondrial fusion and fission. *J. Biol. Chem.*, **2008**, *283*(20), 13501-13505.
- [19] Vermes, I.; Haanen, C.; Steffens-Nakken, H.; Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using

- fluorescein labelled Annexin V. *J. Immunol Methods.*, **1995**, *184*(1), 39-51.
- [20] De Schepper, S.; Bruwiere, H.; Verhulst, T.; Steller, U.; Andries, L.; Wouters, W.; Janicot, M.; Arts, J.; Van Heusden, J. Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin. *J. Pharmacol. Exp. Ther.*, **2003**, *304*(2), 881-888.
- [21] Diggle, C.P.; Bentley, J.; Knowles, M.A.; Kiltie, A.E. Inhibition of double-strand break non-homologous end-joining by cisplatin adducts in human cell extracts. *Nucleic Acids Res.*, **2005**, *33*(8), 2531-2539.
- [22] Hambley, T.W. The influence of structure on the activity and toxicity of Pt anti-cancer drugs. *Coord. Chem. Rev.*, **1997**, *166*, 181-223.
- [23] Zhu, G.; Song, L.; Lippard, S.J. Visualizing inhibition of nucleosome mobility and transcription by cisplatin-DNA interstrand crosslinks in live mammalian cells. *Cancer Res.*, **2013**, *73*(14), 4451-4460.
- [24] Banerjee, T.; Dubey, P.; Mukhopadhyay, R. DNA compaction by mononuclear platinum cancer drug cisplatin and the trisplatinum anticancer agent BBR3464: Differences and similarities. *Biochimie*, **2012**, *94*(2), 494-502.
- [25] Brabec, V. DNA modifications by antitumor platinum and ruthenium compounds: Their recognition and repair. *Prog. Nucleic Acid Res. Mol. Biol.*, **2002**, *71*, 1-68.
- [26] Cohen, S.M.; Lippard, S.J. Cisplatin: From DNA damage to cancer chemotherapy. *Prog. Nucleic Acid Res. Mol. Biol.*, **2001**, *67*, 93-130.
- [27] Jung, Y.; Lippard, S.J. Direct cellular responses to platinum-induced DNA damage. *Chem. Rev.*, **2007**, *107*(5), 1387-1407.
- [28] Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. *Nat. Rev. Drug Discov.*, **2005**, *4*(4), 307-320.
- [29] Fuertes, M.A.; Castilla, J.; Alonso, C.; Perez, J.M. Cisplatin biochemical mechanism of action: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. *Curr. Med. Chem.*, **2003**, *10*(3), 257-266.
- [30] Kartalou, M.; Essigmann, J.M. Recognition of cisplatin adducts by cellular proteins. *Mutat. Res.*, **2001**, *478*(1-2), 1-21.
- [31] Kartalou, M.; Essigmann, J.M. Mechanisms of resistance to cisplatin. *Mutat. Res.*, **2001**, *478*(1-2), 23-43.
- [32] Rabik, C.A.; Dolan, M.E. Molecular mechanisms of resistance and toxicity associated with platinating agent. *Cancer Treat. Rev.*, **2007**, *33*(1), 9-23.
- [33] Krause-Heuer, A.M.; Grunert, R.; Kuhne, S.; Buczkowska, M.; Wheate, N.J.; Le Pevelen, D.D.; Boag, L.R.; Fisher, D.M.; Kasparkova, J.; Malina, J.; Bednarski, P.J.; Brabec, V.; Aldrich-Wright, J.R. Studies of the mechanism of action of platinum(II) complexes with potent cytotoxicity in human cancer cells. *J. Med. Chem.*, **2009**, *52*, 5474-5484.
- [34] Davis, K.J.; Carrall, J.A.; Lai, B.; Aldrich-Wright, J.R.; Ralph, S.F.; Dillon, C.T. Does cytotoxicity of metalointercalators correlate with cellular uptake or DNA affinity? *Dalton Trans.*, **2012**, *41*, 9417-9426.
- [35] Garbutcheon-Singh, K.B.; Myers, S.; Harper, B.W.; Ng, N.S.; Dong, Q.; Xie, C.; Aldrich-Wright, J.R. The effects of 56MESS on mitochondrial and cytoskeletal proteins and the cell cycle in MDCK cells. *Metallomics*, **2013**, *5*, 1061-1067.
- [36] Ng, C.H.; Kong, S.M.; Tiong, Y.L.; Maah, M.J.; Sukram, N.; Ahmad, M.; Khoo, A.S. Selective anticancer copper(II)-mixed ligand complexes: Targeting of ROS and proteasomes. *Metallomics*, **2014**, *6*, 892-906.
- [37] Gatti, L.; Zuco, V.; Zaffaroni, N.; Perego, P. Drug combinations with proteasome inhibitors in antitumor therapy. *Curr. Pharm. Des.*, **2013**, *19*(22), 4094-4114.
- [38] Kazi, A.; Ozcan, S.; Tecleab, A.; Sun, Y.; Lawrence, H.R.; Sebti, S.M. Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity. *J. Biol. Chem.*, **2014**, *289*(17), 11906-11915.
- [39] Chen, D.; Frezza, M.; Schmitt, S.; Kanwar, J.; Dou, Q.P. Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. *Curr. Cancer Drug Targets.*, **2011**, *11*(3), 239-253.
- [40] Alkalay, I.; Yaron, A.; Hatzubai, A.; Orian, A.; Ciechanover, A.; Ben-Neriah, Y. Stimulation-dependent I κ B α phosphorylation marks the NF- κ B inhibitor for degradation via the ubiquitin-proteasome pathway. *Proc. Natl. Acad. Sci. USA*, **1995**, *92*(23), 10599-10603.
- [41] Baldi, L.; Brown, K.; Franzoso, G.; Siebenlist, U. Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I κ B α . *J. Biol. Chem.*, **1996**, *271*(1), 376-379.
- [42] Chen, Z.; Hagler, J.; Palombella, V.J.; Melandri, F.; Scherer, D.; Ballard, D.; Maniatis, T. Signal-induced site-specific phosphorylation targets I κ B α to the ubiquitin-proteasome pathway. *Genes Dev.*, **1995**, *9*(13), 1586-1597.
- [43] Lin, Y.C.; Brown, K.; Siebenlist, U. Activation of NF- κ B requires proteolysis of the inhibitor I κ B- α : Signal-induced phosphorylation of I κ B- α alone does not release active NF- κ B. *Proc. Natl. Acad. Sci. USA*, **1995**, *92*(2), 552-556.
- [44] Roff, M.; Thompson, J.; Rodriguez, M.S.; Jacque, J.M.; Baleux, F.; Arenzana-Seisdedos, F.; Hay, R.T. Role of I κ B α ubiquitination in signal-induced activation of NF- κ B *in vivo*. *J. Biol. Chem.*, **1996**, *271*(13), 7844-7850.
- [45] Chen, C.; Edelstein, L.C.; Gelinas, C. The Rel/NF- κ B family directly activates expression of the apoptosis inhibitor Bcl-xL. *Mol. Cell Biol.*, **2000**, *20*(8), 2687-2695.
- [46] Wang, C.Y.; Mayo, M.W.; Korneluk, R.G.; Goeddel, D.V.; Baldwin, A.S. Jr. NF- κ B antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. *Science*, **1998**, *281*(5383), 1680-1683.
- [47] Wang, C.Y.; Guttridge, D.C.; Mayo, M.W.; Baldwin, A.S. Jr. NF- κ B induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. *Mol. Cell Biol.*, **1999**, *19*(9), 5923-5929.
- [48] Zong, W.X.; Edelstein, L.C.; Chen, C.; Bash, J.; Gélinas, C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF- κ B that blocks TNF α -induced apoptosis. *Genes Dev.*, **1999**, *13*(4), 382-387.
- [49] Kordes, U.; Krappmann, D.; Heissmeyer, V.; Ludwig, W.D.; Scheidereit, C. Transcription factor NF- κ B is constitutively activated in acute lymphoblastic leukemia cells. *Leukemia*, **2000**, *14*(3), 399-402.
- [50] Tricot, G. New insights into role of microenvironment in multiple myeloma. *Lancet*, **2000**, *355*(9200), 248-250.
- [51] Shapovalov, Y.; Benavidez, D.; Zuch, D.; Eliseev, R.A. Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma. *Int. J. Cancer*, **2010**, *127*(1), 67-76.